Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia
- PMID: 31691639
- DOI: 10.2217/pme-2018-0135
Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia
Abstract
Aim: To investigated the potential differences between probable and definite heterozygous familial hypercholesterolemia (HeFH) patients diagnosed by Dutch Lipid Clinic Network criteria. Methods: Clinical characteristics, lipid profile, severity of coronary artery stenosis and gene mutations were compared. Kaplan-Meier curve was performed to evaluate the cardiovascular events. Results: Overall, 325 participants were included and divided into two groups: probable (n = 233) and definite HeFH (n = 92). Definite HeFH patients had higher low-density lipoprotein cholesterol (LDL-C), oxidized-LDL and proprotein convertase subtilisin/kexin 9 levels, and higher prevalence of tendon xanthomas. The incidence of genetic mutations was statistically higher in definite HeFH than probable HeFH patients. The coronary stenosis calculated by Gensini score was statistically severer in definite HeFH patients. The best LDL-C threshold for predicting mutations was 5.14 mmol/l. Definite HeFH had lower event-free survival rates. Conclusion: Definite HeFH patients had higher severity of phenotype and genotype, and higher risk of cardiovascular events.
Keywords: Gensini score; LDL-C threshold; cardiovascular events; gene mutation; heterozygous familial hypercholesterolemia; low-density lipoprotein cholesterol.
Similar articles
-
Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.J Clin Lipidol. 2019 May-Jun;13(3):502-508. doi: 10.1016/j.jacl.2019.02.007. Epub 2019 Mar 11. J Clin Lipidol. 2019. PMID: 30956097
-
Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.Atherosclerosis. 2014 Mar;233(1):219-23. doi: 10.1016/j.atherosclerosis.2013.12.020. Epub 2014 Jan 11. Atherosclerosis. 2014. PMID: 24529147
-
Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia.J Transl Med. 2021 Dec 7;19(1):498. doi: 10.1186/s12967-021-03166-w. J Transl Med. 2021. PMID: 34876165 Free PMC article.
-
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.Atherosclerosis. 2017 Jan;256:134-145. doi: 10.1016/j.atherosclerosis.2016.09.001. Epub 2016 Sep 2. Atherosclerosis. 2017. PMID: 27993383 Review.
-
Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.J Clin Lipidol. 2016 Jul-Aug;10(4):970-986. doi: 10.1016/j.jacl.2016.04.009. Epub 2016 May 5. J Clin Lipidol. 2016. PMID: 27578130 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources